U.S. Entertainment Stock News

NYSE:FLUT
NYSE:FLUTHospitality

A Look At Flutter Entertainment’s Valuation As FanDuel Launches New World Cup Coaches Corner Series

Flutter Entertainment (NYSE:FLUT) is back on investor radars after its FanDuel unit unveiled Coaches Corner, a 10 episode World Cup themed series featuring three former United States Men's Soccer head coaches. See our latest analysis for Flutter Entertainment. The latest share price of US$95.75 comes after a 1 day share price return of 2.07%, but the 30 day share price return is down 13.68% and the 1 year total shareholder return is down 61.22%, pointing to fading momentum despite content...
NYSE:VIK
NYSE:VIKHospitality

Is It Too Late To Consider Viking Holdings (VIK) After A 109% One Year Rally?

If you are wondering whether Viking Holdings stock still offers value after a strong run, or if you might be late to the story, this article breaks down what the current price could be indicating. The stock last closed at US$92.55, with returns of 11.3% over 7 days, 14.5% over 30 days, 28.1% year to date, and 108.8% over the past year. This performance may have reshaped how many investors think about its risk and reward profile. Recent coverage has focused on Viking Holdings as a major...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

A Look At Expedia Group (EXPE) Valuation As B2B AI And CarTrawler Deal Expand Travel Tech Ambitions

Expedia Group (EXPE) is in focus after its B2B arm outlined new AI powered products, an agreement to acquire CarTrawler, and fresh merchandising and advertising tools aimed at partners across sectors. See our latest analysis for Expedia Group. The recent AI focused B2B announcements, the planned CarTrawler acquisition, and the CLEAR partnership come as Expedia Group trades at US$226.56, with a 7 day share price return of 4.12%, a year to date share price return that is down 19.93%, and a 3...
NYSE:RVTY
NYSE:RVTYLife Sciences

Revvity (RVTY) Valuation Check After Mixed Recent Share Performance

Revvity (RVTY) has been drawing attention after a period of mixed share performance. The stock is roughly flat year to date, higher over the past month, and lower over the past three months. See our latest analysis for Revvity. Revvity’s recent 11.51% 30 day share price return contrasts with a 1.39% decline year to date. The 1 year total shareholder return of 6.27% sits against weaker 3 and 5 year outcomes, suggesting short term momentum against a softer longer term record. If you are...
NYSE:MTN
NYSE:MTNHospitality

A Look At Vail Resorts (MTN) Valuation After Recent Share Price Rebound

Why Vail Resorts stock is back on investor watchlists Vail Resorts (MTN) has drawn fresh attention after a recent share move, with the stock up about 3.6% over the past week and roughly 8.9% over the past month on renewed interest in its resort-focused business. See our latest analysis for Vail Resorts. That short burst of share price momentum, including a 1 month share price return of 8.9%, comes after a weaker patch where the 1 year total shareholder return is down 15.2% and the 5 year...
NasdaqGS:CEVA
NasdaqGS:CEVASemiconductor

A Look At CEVA (CEVA) Valuation After Analyst Upgrades And Earnings Outlook Shift

Recent interest in CEVA (CEVA) has picked up after analyst upgrades and improved full year earnings estimates, with investors also watching the stock ahead of its presentations at two major technology conferences. See our latest analysis for CEVA. The recent analyst upgrades and conference appearances come against a backdrop of strong momentum, with CEVA’s share price delivering a 49.41% 1 month return and an 80.87% year to date return, while the 1 year total shareholder return sits at...
NYSE:VEEV
NYSE:VEEVHealthcare Services

Is It Time To Reconsider Veeva Systems (VEEV) After Recent Share Price Weakness

If you are wondering whether Veeva Systems at US$158.49 is starting to look like value or still prices in high expectations, the next sections walk through what the numbers say about the stock. The share price has fallen 3.9% over the past week, 1.2% over the past month, and is down 27.8% year to date and 32.4% over the last year, which can change how the market views both risk and potential reward. These moves sit against a backdrop where investors continue to focus on Veeva Systems' role...
NYSE:A
NYSE:ALife Sciences

Agilent Product Suite Refresh Raises Questions On Adoption And Valuation Potential

Agilent Technologies (NYSE:A) has introduced a suite of new laboratory instruments, including the 8890B and 8860B GC with GC Assist, a MAM workflow for biopharma QC labs, the 9500 Triple Quadrupole ICP-MS, and the 1290 Infinity III Fluorescence Detector. The launches target chromatography, mass spectrometry, and quality control workflows, with a focus on automation, remote monitoring, and regulatory support across pharma, food, environmental, and materials labs. These products represent a...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Is Medpace’s New Shareholder Powers Regime Altering The Investment Case For Medpace Holdings (MEDP)?

At Medpace Holdings' 2026 Annual Meeting, shareholders approved amendments to the Restated Certificate of Incorporation and bylaws that removed supermajority voting rules and expanded the ability of investors owning at least 25% of voting power to call special meetings, changes that became effective on May 18, 2026. This shift meaningfully increases shareholder influence over corporate decisions, potentially changing how actively investors engage with Medpace’s board and long-term governance...
NYSE:DOW
NYSE:DOWChemicals

Is It Too Late To Consider Dow (DOW) After A 42% Year To Date Surge

If you are wondering whether Dow at US$34.49 is still offering value after a strong run, this breakdown will help you frame that question with numbers, not guesswork. The stock is up 42.1% year to date and 29.9% over the past year, even though it has fallen 4.9% over the last week and 9.5% over the last month, which can change how the market is viewing both opportunity and risk. Recent coverage has focused on Dow as a key player in the US materials sector, with attention on how its share...
NYSE:BABA
NYSE:BABAMultiline Retail

A Look At Alibaba Group Holding’s Valuation After Recent Share Price Weakness

Recent performance snapshot for Alibaba Group Holding (BABA) Alibaba Group Holding (NYSE:BABA) stock has been under pressure recently, with the price closing at US$127.76 and showing declines over the past week, month, past 3 months and year to date. Despite these pullbacks, Alibaba reports revenue of CN¥1,023,670 and net income of CN¥105,904, with annual revenue and net income growth figures provided and a market cap of about US$295.6b. See our latest analysis for Alibaba Group...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

How Investors May Respond To Natera (NTRA) Boosting Panorama NIPT And Scaling Sequencing Capacity

Natera, Inc. recently enhanced its Panorama non-invasive prenatal test with SNP-informed deep sequencing, showing strong performance even in low fetal fraction samples and cutting the no-call rate to 0.5%, and expanded its Austin headquarters with what it expects will be the largest sequencing capacity in the world to meet rising testing demand. These advances highlight how Natera is pairing clinically-validated improvements in prenatal screening with major infrastructure investment, aiming...
NasdaqGS:HURN
NasdaqGS:HURNProfessional Services

Huron Consulting Group’s Revenue Growth Vs Share Price Pullback Attracts Scrutiny

Huron Consulting Group reported an 11.8% year-on-year revenue increase in its latest first quarter. The company exceeded earnings expectations, reflecting continued operational improvement. These results extend a multi year pattern of growth and capital returns, including share repurchases. The update arrives as NasdaqGS:HURN trades at $104.74 after a recent pullback in the share price. For investors tracking NasdaqGS:HURN, the picture is mixed at first glance. The stock is down 17.6% over...
NasdaqGS:KDP
NasdaqGS:KDPBeverage

How Keurig Dr Pepper’s Reaffirmed Dividend and Rising Demand Will Impact Keurig Dr Pepper (KDP) Investors

Keurig Dr Pepper Inc. recently confirmed a quarterly dividend of US$0.23 per share, payable on July 10, 2026, to shareholders of record as of June 26, 2026, with the same date as the ex-dividend date. This reaffirmed payout comes as the company’s beverage portfolio experiences accelerating unit demand and Wall Street anticipates robust revenue growth over the next year. Against this backdrop of reaffirmed dividends and accelerating beverage demand, we’ll explore how the news may reshape...
NasdaqGS:KYIV
NasdaqGS:KYIVWireless Telecom

Assessing Kyivstar Group (NasdaqGS:KYIV) Valuation After Recent Share Price Momentum

What recent performance in Kyivstar Group (KYIV) suggests for investors Without a clear single news catalyst, Kyivstar Group (KYIV) has still drawn attention after a month return of 24.9% and a past 3 months return of 21.9%, prompting closer scrutiny of its fundamentals and valuation. See our latest analysis for Kyivstar Group. Kyivstar Group’s recent 30 day share price return of 24.9% and 90 day share price return of 21.9%, alongside a 1 year total shareholder return of 19%, suggest building...
NYSE:PG
NYSE:PGHousehold Products

How Investors May Respond To Procter & Gamble (PG) Expanding U.S. Logistics With New Georgia Facility

Earlier in May, Procter & Gamble announced a US$205 million investment in a new automated distribution facility in Georgia, aimed at boosting U.S. logistics capacity and supporting its broad consumer products network. This expansion underlines P&G’s push to reinforce its role as a resilient, income-focused consumer staples group, backed by a multi-decade record of dividend growth that appeals to investors seeking stability. Next, we’ll examine how P&G’s new Georgia distribution investment...
NasdaqGS:DBX
NasdaqGS:DBXSoftware

Assessing Dropbox (DBX) Valuation After Recent Leadership And Governance Changes

Dropbox (DBX) has entered a leadership transition, with Ashraf Alkarmi appointed Co Chief Executive Officer alongside co founder Andrew Houston. Houston is expected to move into the Executive Chairman role after a transition period. See our latest analysis for Dropbox. At a share price of US$25.97, Dropbox has seen short term pressure, with the 7 day share price return down 5.77%, even though the 30 day share price return is up 8.62% and the 3 year total shareholder return is up 12.81%. This...
NYSE:CRM
NYSE:CRMSoftware

Salesforce (CRM) Valuation Check As Shares Extend Recent Three Month Decline

What Salesforce (CRM) investors are looking at now Salesforce (CRM) currently trades at US$177.51, with the stock down about 1% over the past week and about 1% over the past month, extending a decline of roughly 11% in the past 3 months. See our latest analysis for Salesforce. Looking beyond the recent pullback, Salesforce’s share price return is down 30% year to date and the 1 year total shareholder return has declined 35.21%, suggesting momentum has been fading rather than building. If...
NasdaqCM:VRRM
NasdaqCM:VRRMProfessional Services

Assessing Verra Mobility (VRRM) Valuation After Recent Share Price Weakness

Stock performance snapshot Verra Mobility (VRRM) has been under pressure, with the stock down about 0.7% over the past day and roughly 0.8% year to date, while the past year and past 3 months also reflect sizeable declines. At a recent close of US$3.85 and a market cap of about US$2.0b, the company sits against a backdrop of reported annual revenue of US$979.39m and net income of US$131.04m across its three core segments. See our latest analysis for Verra Mobility. The recent share price...
NYSE:ABBV
NYSE:ABBVBiotechs

Is AbbVie (ABBV) Still Attractive After A 21.5% One Year Share Price Gain?

If you are wondering whether AbbVie stock still offers value after a strong run, it is important to see how different valuation methods line up against the current share price. The stock recently closed at US$215.40, with returns of 1.5% over the past week, 9.1% over the past month, and 21.5% over the past year, while year to date it is down 6.1%. Recent coverage has focused on AbbVie's position in the large cap pharmaceuticals and biotech space and how investors weigh long term drug...
NYSE:ZWS
NYSE:ZWSBuilding

A Look At Zurn Elkay Water Solutions (ZWS) Valuation After New CFO And COO Promotions

Zurn Elkay Water Solutions (ZWS) has reshuffled its leadership team, promoting long-time executives Dan Klun to Chief Financial Officer and Dave Pauli to Chief Operating Officer, moves that put experienced insiders in key decision making roles. See our latest analysis for Zurn Elkay Water Solutions. The executive reshuffle comes as Zurn Elkay’s share price sits at US$48.80, with a year to date share price return of 4.16% and a 1 year total shareholder return of 34.94%, pointing to momentum...
NYSE:CARR
NYSE:CARRBuilding

Diamond Hill Capital Backs Carrier Global Story On Margins And Growth

Diamond Hill Capital has initiated a new position in Carrier Global (NYSE:CARR), focusing on the company's resilience and operational strengths. The investment highlights expectations for market share gains and margin improvement opportunities, despite current pressure in residential markets. The move adds another institutional holder to Carrier Global's shareholder base at a share price of $64.51. For you as an investor, this fresh interest in NYSE:CARR comes as the stock trades around...
NYSE:BAC
NYSE:BACBanks

How Investors Are Reacting To Bank of America (BAC) Q1 Beat, New Funding Moves and Tech Push

Earlier in May 2026, Bank of America reported Q1 results that exceeded analyst expectations for both revenue and GAAP EPS, while also continuing to expand its fixed-income funding with multiple new senior unsecured note offerings across a range of maturities and coupons. These developments, combined with increased attention on the bank’s digital platform and its role in broader themes such as AI-driven power demand and major philanthropic partnerships like the Boston Marathon, highlight how...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

Will Widening Losses and Renewed Buy Ratings Change Belite Bio's (BLTE) Narrative?

Belite Bio, Inc recently reported a first-quarter 2026 net loss of US$26.94 million, widening from US$14.28 million a year earlier, and participated in the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026), where Ruifang Sui presented on the company’s retinal disease work. Even as losses increased and the company remains pre-revenue, renewed Buy ratings from major brokers and scientific visibility at Retina China 2026 have kept attention on Belite Bio’s...